SCHEMBL2179148

SCHEMBL2179148

CS(=O)(=O)c1cccc(-c2cnc3[nH]cc(COCc4ccc(NCc5ccc(Cl)cc5)nc4)c3c2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.45
CYP2C19 P33261 4/20 0.45
CYP2D6 P10635 1/20 0.45
CAMKK2 Q96RR4 2/20 0.44
CSF1R P07333 2/20 0.43
KIT P10721 2/20 0.43
LCK P06239 1/20 0.43
PGR P06401 1/20 0.43
CHRM2 P08172 1/20 0.43
HTR1A P08908 1/20 0.43
ADRA2A P08913 1/20 0.43
PDGFRB P09619 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
CHRM1 P11229 1/20 0.43
PDGFRA P16234 1/20 0.43
FLT1 P17948 1/20 0.43
DRD1 P21728 1/20 0.43
TBXA2R P21731 1/20 0.43
SLC6A2 P23975 1/20 0.43
ADORA1 P30542 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL878787 0.81 CAMKK2 (0.42) CYP3A4CYP2C19CYP2D6CAMKK2CSF1R
SCHEMBL1267958 0.69 CYP3A4 (0.83) CYP3A4CYP2C19CYP2D6CSF1RKIT
SCHEMBL2181556 0.69 CYP3A4 (0.69) CYP3A4CYP2C19CYP2D6CSF1RKIT
SCHEMBL1267844 0.68 CSF1R (0.77) CYP3A4CYP2C19CYP2D6CSF1RKIT
SCHEMBL4165835 0.68 CAMKK2 (0.74) CAMKK2CSF1RKITLCKFLT1
SCHEMBL4166523 0.68 CAMKK2 (0.63) CAMKK2KITPLK4RIPK1
SCHEMBL14620861 0.67 CYP3A4 (0.69) CYP3A4CYP2C19CYP2D6CSF1RKIT
SCHEMBL857477 0.67 CYP3A4 (0.69) CYP3A4CYP2C19CYP2D6CSF1RKIT
SCHEMBL858795 0.67 CAMKK2 (0.52) CYP3A4CYP2C19CAMKK2PLK4RIPK1
SCHEMBL7867667 0.66 CAMKK2 (0.61) CAMKK2KITPLK4RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110166174-A1 COMPOUNDS MODULATING C-KIT AND C-FMS ACTIVITY AND USES THEREFOR PLEXXIKON, INC. 2011-07-07 US disclosed
US-7846941-B2 Compounds modulating c-kit and c-fms activity and uses therefor PLEXXIKON, INC. (US) 2010-12-07 US disclosed
US-20070032519-A1 Compounds modulating c-kit and c-fms activity and uses therefor PLEXXIKON, INC. 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166174-A1 COMPOUNDS MODULATING C-KIT AND C-FMS ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 CYP3A4 3915/4885CYP2C19 3012/4885CYP2D6 4024/4885
US-20070032519-A1 Compounds modulating c-kit and c-fms activity and uses therefor KIT, FLT3, FLT1 CYP3A4 3915/4885CYP2C19 3012/4885CYP2D6 4024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.